Area of research
Pulmonary and Respiratory Medicine · Gastroenterology
Research interest
Research interests include Gastrointestinal Tumor Research and Treatment, Sarcoma Diagnosis and Treatment, Gastric Cancer Management and Outcomes, and Cancer Genomics and Diagnostics.
Digitally engaging participants in cancer clinical trials: Design and pilot of the Alliance Participant Engagement Portal (PEP).
Multi-Omic Landscape of Gastrointestinal Stromal Tumors in a Real-World Patient Cohort of 1,427 Cases.
A Phase 2 Study of the Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma (EHE).
Genomic Profiling of Cardiac Angiosarcoma Reveals Novel Targetable KDR Variants, Recurrent MED12 Mutations, and a High Burden of Germline POT1 Alterations.
Navigating Ongoing Challenges in GI Stromal Tumors.
Challenges in Automating Extraction of Real-World Radiographic Images and Adverse Events: Lessons From the ICAREdata Initiative.
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE.
Supplementary Figure S5 from Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma
Supplementary Table S2 from Genomic Profiling of Cardiac Angiosarcoma Reveals Novel Targetable <i>KDR</i> Variants, Recurrent <i>MED12</i> Mutations, and a High Burden of Germline <i>POT1</i> Alterations
Supplementary Figure S1 from Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma
Supplementary Figure S10 from Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma
Data from Genomic Profiling of Cardiac Angiosarcoma Reveals Novel Targetable <i>KDR</i> Variants, Recurrent <i>MED12</i> Mutations, and a High Burden of Germline <i>POT1</i> Alterations
Supplementary Table S5 from Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma
Supplementary Figure S3 from Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma
Supplementary Table S3 from Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma
Supplementary Table S4 from Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma
Supplementary Table S1 from Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma
Supplementary Figure S11 from Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma
supplementary table TS1 from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
Supplementary Table S1 from Genomic Profiling of Cardiac Angiosarcoma Reveals Novel Targetable <i>KDR</i> Variants, Recurrent <i>MED12</i> Mutations, and a High Burden of Germline <i>POT1</i> Alterations
Supplementary Figure S8 from Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma
Supplementary Figure S1 from A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor
Supplementary Figure S6 from Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma
Supplementary Figure S4 from Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma
Supplementary Table S2 from Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma
Supplementary Figure S3 from Genomic Profiling of Cardiac Angiosarcoma Reveals Novel Targetable <i>KDR</i> Variants, Recurrent <i>MED12</i> Mutations, and a High Burden of Germline <i>POT1</i> Alterations
Supplementary Figure S7 from Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma
Supplementary Figure S2 from A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor
Supplementary Figure S1 from Genomic Profiling of Cardiac Angiosarcoma Reveals Novel Targetable <i>KDR</i> Variants, Recurrent <i>MED12</i> Mutations, and a High Burden of Germline <i>POT1</i> Alterations
Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)